Connection

Michael Hallek to Quinazolines

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Quinazolines.
Michael Hallek
Connection Strength
0.715
Quinazolines
  1. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 2018; 12:2577-2590.
    View in: PubMed
    Score: 0.673
  2. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018 10; 37(42):5682-5693.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.